2016 DILI Conference XVI: How Should Liver Injury and Dysfunction Caused by Drugs Be Measured, Evaluated, and Acted Upon in Clinical Trials?
The 2016 DILI Conference XVI: How Should Liver Injury and Dysfunction Caused by Drugs Be Measured, Evaluated, and Acted Upon in Clinical Trials? The meeting will be held Wednesday and Thursday, March 23-24, 2016 at the Marriott Inn & Conference Center, University of Maryland University College 3501 University Blvd., East Hyattsville, MD 20783.
Goals and Objectives
The purpose of this scientific workshop is to discuss ways in which to measure, evaluate and act upon liver injury and dysfunction caused by drugs in clinical trials.
Who Should Attend
This workshop is intended for a diverse group of scientists from FDA, C-Path’s PSTC, representatives from the pharmaceutical industry, and other interested parties regarding ongoing efforts on research and development of safety biomarkers and drug development tools.
The primary audience includes leading academic experts, interested pharmaceutical companies, regulatory agencies, patient advocacy groups, non-profit organizations, scientists, clinicians from regulatory, academic, industrial and other healthcare sectors, scientists involved in drug development in those same industries, pharmacokineticists (clinical, preclinical, and toxicokinetics) who are involved in qualification of safety biomarkers or directly impacted by the qualification of safety biomarkers for drug development.
How to Register
Please visit this link-- http://www.cvent.com/events/drug-induced-liver-injury-dili-conference-xvi-how-should-liver-injury-and-dysfunction-caused-by-drug/invitation-f401de5ad100454099bc713b19efd971.aspx?i=3304dbfd-d41d-4527-bd6e-4d85aff0b2c6
Lana L. Pauls, MPH (firstname.lastname@example.org), or 301-796-0518.